clofibrate has been researched along with Myocardial Infarction in 109 studies
angiokapsul: contains clofibrate & insoitolnicotinate
Myocardial Infarction: NECROSIS of the MYOCARDIUM caused by an obstruction of the blood supply to the heart (CORONARY CIRCULATION).
| Excerpt | Relevance | Reference |
|---|---|---|
| " Therefore, our aim was to study if clofibrate treatment was capable of decreasing inflammation and apoptosis, and reverse ventricular remodeling and MI-induced functional damage." | 7.91 | Clofibrate Treatment Decreases Inflammation and Reverses Myocardial Infarction-Induced Remodelation in a Rodent Experimental Model. ( Cervantes-Pérez, LG; Ibarra-Lara, L; Pastelín-Hernández, G; Pavón, N; Roldán, FJ; Sánchez-Aguilar, M; Sánchez-Mendoza, A; Soria-Castro, E; Torres-Narváez, JC; Vargas-Barrón, J, 2019) |
| "The study was designed to characterise the influence of a novel acyl-CoA:cholesterol acyltransferase inhibitor, VULM 1457, on the severity of myocardial ischaemia-reperfusion injury in a model of diabetes mellitus and hypercholesterolaemia induced by co-administration of streptozotocin and a high fat-cholesterol diet." | 7.74 | The myocardial infarct size-limiting and antiarrhythmic effects of acyl-CoA:cholesterol acyltransferase inhibitor VULM 1457 protect the hearts of diabetic-hypercholesterolaemic rats against ischaemia/reperfusion injury both in vitro and in vivo. ( Adameová, A; Faberová, V; Kuzelová, M; Ravingerová, T; Svec, P, 2007) |
| "Male and female, arteriosclerotic and non-arteriosclerotic rats were treated with the anti-lipemic agent, clofibrate, for 8 days and then subjected to an acute myocardial infarction by injecting them with two large doses of isoproterenol spaced 24 hours apart." | 7.66 | Protective effects of clofibrate on isoproterenol-induced myocardial infarction in arteriosclerotic and non-arteriosclerotic rats. ( Greenberg, BP; Wexler, BC, 1978) |
| "Clofibrate was fed to experimental pigs for 9 days." | 5.27 | Improved myocardial performance induced by clofibrate during reperfusion after acute myocardial infarction. ( Breyer, RH; Clement, R; Das, DK; Engelman, RM; Jones, R; Otani, H; Prasad, MR; Rousou, JA, 1988) |
| " Therefore, our aim was to study if clofibrate treatment was capable of decreasing inflammation and apoptosis, and reverse ventricular remodeling and MI-induced functional damage." | 3.91 | Clofibrate Treatment Decreases Inflammation and Reverses Myocardial Infarction-Induced Remodelation in a Rodent Experimental Model. ( Cervantes-Pérez, LG; Ibarra-Lara, L; Pastelín-Hernández, G; Pavón, N; Roldán, FJ; Sánchez-Aguilar, M; Sánchez-Mendoza, A; Soria-Castro, E; Torres-Narváez, JC; Vargas-Barrón, J, 2019) |
| "The study was designed to characterise the influence of a novel acyl-CoA:cholesterol acyltransferase inhibitor, VULM 1457, on the severity of myocardial ischaemia-reperfusion injury in a model of diabetes mellitus and hypercholesterolaemia induced by co-administration of streptozotocin and a high fat-cholesterol diet." | 3.74 | The myocardial infarct size-limiting and antiarrhythmic effects of acyl-CoA:cholesterol acyltransferase inhibitor VULM 1457 protect the hearts of diabetic-hypercholesterolaemic rats against ischaemia/reperfusion injury both in vitro and in vivo. ( Adameová, A; Faberová, V; Kuzelová, M; Ravingerová, T; Svec, P, 2007) |
| "This study was designed to investigate the effects of two, chemically distinct activators of PPAR-a (clofibrate and WY14643) in a rat model of acute myocardial infarction." | 3.71 | Ligands of the peroxisome proliferator-activated receptor-PPAR-a reduce myocardial infarct size. ( Ellis, BL; Thiemermann, C; Wayman, NS, 2002) |
| "(1) In primary prevention trials, pravastatin and lovastatin prevented myocardial infarction and had a positive risk-benefit ratio in men with LDL-cholesterol values exceeding 4." | 3.70 | Cholesterol-lowering drugs. Some drugs with demonstrated efficacy but different benefits in primary and secondary prevention. ( , 1999) |
| "Results of recent clinical trials on secondary prevention of ischemic heart disease indicate that judicious, long-term administration of adrenergic beta blockers and platelet-active drugs such as aspirin and Persantine (dipyridamole) would seem to yield protection against mortality associated with acute myocardial infarction, including sudden death." | 3.67 | Clinical trials on the efficacy of pharmacologic intervention reducing mortality from cardiovascular diseases. ( Borhani, NO, 1985) |
| "Male and female, arteriosclerotic and non-arteriosclerotic rats were treated with the anti-lipemic agent, clofibrate, for 8 days and then subjected to an acute myocardial infarction by injecting them with two large doses of isoproterenol spaced 24 hours apart." | 3.66 | Protective effects of clofibrate on isoproterenol-induced myocardial infarction in arteriosclerotic and non-arteriosclerotic rats. ( Greenberg, BP; Wexler, BC, 1978) |
| "Niacin treatment showed modest benefit in decreasing definite nonfatal recurrent myocardial infarction but did not decrease total mortality." | 2.66 | Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. ( Berge, KG; Canner, PL; Friedewald, W; Friedman, L; Prineas, RJ; Stamler, J; Wenger, NK, 1986) |
| "Clofibrate treatment coincided with increasing amounts of monounsaturated fatty acids, especially oleate (18 : 1), in the cholesterol esters, triglycerides and phospholipids while there were significant reductions of the content of linoleic (18 : 2) acid in both the cholesterol esters and triglycerides." | 2.65 | Changes in the fatty acid composition of the plasma lipid esters during lipid-lowering treatment with diet, clofibrate and niceritrol. Reduction of the proportion of linoleate by clofibrate but not by niceritrol. ( Boberg, J; Gustafsson, IB; Lithell, H; Vessby, B, 1980) |
| "Clofibrate treatment prevented MI-induced changes in iNOS, MMP-2 and MMP-9, ICAM-1, IL-6, NF-κB, and IκB." | 1.43 | Peroxisome proliferator-activated receptors (PPAR) downregulate the expression of pro-inflammatory molecules in an experimental model of myocardial infarction. ( Cervantes-Pérez, LG; Del Valle-Mondragón, L; Ibarra-Lara, Mde L; Oidor-Chan, VH; Pastelín-Hernández, G; Pérez-Severiano, F; Ramírez-Ortega, Mdel C; Sánchez-Aguilar, M; Sánchez-Mendoza, A; Soria, E; Torres-Narváez, JC, 2016) |
| "Clofibrate was fed to experimental pigs for 9 days." | 1.27 | Improved myocardial performance induced by clofibrate during reperfusion after acute myocardial infarction. ( Breyer, RH; Clement, R; Das, DK; Engelman, RM; Jones, R; Otani, H; Prasad, MR; Rousou, JA, 1988) |
| "and sulfinpyrazone have been tested in several large scale clinical trials." | 1.26 | [Antiplatelet drugs (author's transl)]. ( Dechavanne, M; Follea, G; Trzeciak, MC, 1979) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 98 (89.91) | 18.7374 |
| 1990's | 3 (2.75) | 18.2507 |
| 2000's | 5 (4.59) | 29.6817 |
| 2010's | 3 (2.75) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ibarra-Lara, L | 1 |
| Sánchez-Aguilar, M | 2 |
| Soria-Castro, E | 1 |
| Vargas-Barrón, J | 1 |
| Roldán, FJ | 1 |
| Pavón, N | 1 |
| Torres-Narváez, JC | 2 |
| Cervantes-Pérez, LG | 2 |
| Pastelín-Hernández, G | 2 |
| Sánchez-Mendoza, A | 2 |
| Wang, D | 1 |
| Liu, B | 1 |
| Tao, W | 1 |
| Hao, Z | 1 |
| Liu, M | 1 |
| Ibarra-Lara, Mde L | 1 |
| Soria, E | 1 |
| Del Valle-Mondragón, L | 1 |
| Pérez-Severiano, F | 1 |
| Ramírez-Ortega, Mdel C | 1 |
| Oidor-Chan, VH | 1 |
| Wayman, NS | 2 |
| Ellis, BL | 1 |
| Thiemermann, C | 2 |
| Corvol, JC | 1 |
| Bouzamondo, A | 1 |
| Sirol, M | 1 |
| Hulot, JS | 1 |
| Sanchez, P | 1 |
| Lechat, P | 1 |
| SYMONS, C | 1 |
| DETOSZEGHI, A | 1 |
| COOK, IJ | 1 |
| Adameová, A | 1 |
| Ravingerová, T | 1 |
| Svec, P | 1 |
| Faberová, V | 1 |
| Kuzelová, M | 1 |
| Avellone, G | 1 |
| Mandalà, V | 1 |
| Novo, S | 1 |
| Pinto, A | 1 |
| Riolo, FP | 1 |
| Davì, G | 1 |
| Raneli, G | 1 |
| Oliver, MF | 4 |
| Hanefeld, M | 1 |
| Hora, C | 1 |
| Schulze, J | 1 |
| Rothe, G | 1 |
| Barthel, U | 1 |
| Haller, H | 1 |
| Vessby, B | 1 |
| Lithell, H | 1 |
| Gustafsson, IB | 1 |
| Boberg, J | 1 |
| Hirsh, J | 4 |
| May, GS | 1 |
| DeMets, DL | 1 |
| Friedman, LM | 1 |
| Furberg, C | 1 |
| Passamani, E | 1 |
| Lamm, G | 1 |
| Reuter, W | 1 |
| Fabbrocini, V | 1 |
| Walldius, G | 1 |
| Rosenhamer, G | 3 |
| Carlson, LA | 5 |
| Croveri, G | 1 |
| Horwitz, RI | 1 |
| Horwitz, SM | 1 |
| Holme, I | 1 |
| Klungel, OH | 1 |
| Heckbert, SR | 1 |
| de Boer, A | 1 |
| Leufkens, HG | 1 |
| Sullivan, SD | 1 |
| Fishman, PA | 1 |
| Veenstra, DL | 1 |
| Psaty, BM | 1 |
| Hattori, Y | 1 |
| McDonald, MC | 1 |
| Mota-Filipe, H | 1 |
| Cuzzocrea, S | 1 |
| Pisano, B | 1 |
| Chatterjee, PK | 1 |
| Haft, JI | 1 |
| Cederblad, G | 1 |
| Korsan-Bengtsen, K | 1 |
| Schettler, G | 1 |
| Wenger, NK | 2 |
| Stamler, J | 3 |
| Borhani, NO | 2 |
| Verstraete, M | 4 |
| Yasunaga, K | 1 |
| Vaisrub, S | 1 |
| Gantmacher, ML | 1 |
| Mamchenko, GF | 1 |
| Kritchevsky, D | 1 |
| Dechavanne, M | 1 |
| Follea, G | 1 |
| Trzeciak, MC | 1 |
| Blakely, JA | 1 |
| Wexler, BC | 1 |
| Greenberg, BP | 1 |
| Rössner, S | 2 |
| Werkö, L | 2 |
| Weiss, HJ | 1 |
| Gallus, AS | 1 |
| Aledort, LM | 1 |
| Marek, H | 1 |
| Kuklinski, B | 1 |
| Hunger, R | 1 |
| Danielson, M | 1 |
| Ekberg, I | 1 |
| Klintemar, B | 1 |
| Mustard, JF | 1 |
| Packham, MA | 1 |
| Kinlough-Rathbone, RL | 1 |
| Inoue, Y | 1 |
| Gent, M | 2 |
| Genton, E | 2 |
| Harker, LA | 1 |
| Dubach, UC | 1 |
| Prasad, MR | 1 |
| Clement, R | 1 |
| Otani, H | 1 |
| Jones, R | 1 |
| Das, DK | 1 |
| Engelman, RM | 1 |
| Breyer, RH | 1 |
| Rousou, JA | 1 |
| Schmidt, J | 1 |
| Canner, PL | 1 |
| Berge, KG | 1 |
| Friedman, L | 1 |
| Prineas, RJ | 1 |
| Friedewald, W | 1 |
| Gerö, S | 1 |
| Wilson, DE | 1 |
| Lees, RS | 1 |
| Savoie, LL | 1 |
| Doĭchinov, A | 1 |
| Buchvarova, B | 1 |
| McNicol, GP | 1 |
| Davies, JA | 1 |
| Dewar, HA | 3 |
| Kusá, O | 2 |
| Eastham, RD | 1 |
| Bavina, MV | 1 |
| Perova, NV | 1 |
| Lobova, NM | 1 |
| Koropova, GI | 1 |
| Gillam, PM | 1 |
| Mitchell, WD | 1 |
| Murchison, LE | 1 |
| Amidi, M | 1 |
| Friedewald, WT | 1 |
| Halperin, M | 1 |
| Krasno, LR | 1 |
| Kidera, GJ | 1 |
| Poleszak, J | 1 |
| Korolko, A | 1 |
| Begg, TB | 1 |
| Rifkind, BM | 1 |
| Fearnley, GR | 1 |
| Irsigler, K | 1 |
| Flegel, U | 1 |
| Page, IH | 1 |
| Lewis, LA | 1 |
| Fejfar, Z | 1 |
| Vanĕcek, R | 1 |
| Kaunitz, H | 1 |
| Storey, GO | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Development and Evaluation of a Therapeutic Education Intervention Focused on the Accession of Patients Treated With Hormonal Therapy in the Management of Breast Cancer: PEPs Hormonotherapy[NCT02300675] | 352 participants (Actual) | Interventional | 2014-05-31 | Completed | |||
| [NCT00000482] | Phase 3 | 0 participants | Interventional | 1965-04-30 | Completed | ||
| [NCT00000483] | 0 participants | Interventional | 1981-06-30 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
19 reviews available for clofibrate and Myocardial Infarction
| Article | Year |
|---|---|
Fibrates for secondary prevention of cardiovascular disease and stroke.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Bezafibrate; Cardiovascular Diseases; Caus | 2015 |
Differential effects of lipid-lowering therapies on stroke prevention: a meta-analysis of randomized trials.
Topics: Anticholesteremic Agents; Atorvastatin; Cholestyramine Resin; Clofibrate; Colestipol; Gemfibrozil; H | 2003 |
[Platelet anti-aggregant drugs and ischemic cardiopathy: evaluation of the effect on platelet aggregation and on antithrombin III].
Topics: Adult; Anticoagulants; Antithrombin III; Arrhythmias, Cardiac; Clofibrate; Dipyridamole; Female; Hum | 1981 |
Selection and results of antiplatelet therapy in the prevention of stroke and myocardial infarction.
Topics: Adult; Aspirin; Blood Platelets; Cerebrovascular Disorders; Clinical Trials as Topic; Clofibrate; Di | 1981 |
The randomized clinical trial: bias in analysis.
Topics: Acute Disease; Alprenolol; Atenolol; Clinical Trials as Topic; Clofibrate; Double-Blind Method; Huma | 1981 |
The cardiovascular disease programme of WHO/EURO. A critical review of its first 12 years.
Topics: Adult; Cardiovascular Diseases; Clinical Trials as Topic; Clofibrate; Coronary Disease; Double-Blind | 1981 |
Adherence to treatment and health outcomes.
Topics: Clofibrate; Double-Blind Method; Evaluation Studies as Topic; Humans; Hypercholesterolemia; Male; My | 1993 |
Relationship between total mortality and cholesterol reduction as found by meta-regression analysis of randomized cholesterol-lowering trials.
Topics: Anticholesteremic Agents; Cholesterol; Clofibrate; Coronary Disease; Humans; Myocardial Infarction; | 1996 |
Role of blood platelets in coronary artery disease.
Topics: Adrenergic beta-Antagonists; Arrhythmias, Cardiac; Aspirin; Clinical Trials as Topic; Clofibrate; Co | 1979 |
Primary prevention of coronary heart disease: a critique.
Topics: Adult; Blood Pressure; Cholesterol; Clofibrate; Coronary Disease; Dextrothyroxine; Dietary Carbohydr | 1977 |
[Indications and uncertainties of antiaggregating agents].
Topics: Anticoagulants; Aspirin; Clofibrate; Dipyridamole; Humans; Myocardial Infarction; Platelet Aggregati | 1977 |
[Clinical application and evaluation of anti-platelet agents].
Topics: Aged; Aspirin; Blood Platelets; Clinical Trials as Topic; Clofibrate; Dipyridamole; Drug Evaluation; | 1978 |
[Prophylactic value of platelet anti-aggregants in coronary disease].
Topics: Anticoagulants; Arteriosclerosis; Aspirin; Clofibrate; Coronary Disease; Dipyridamole; Embolism; Hea | 1979 |
Antiplatelet agents: a review.
Topics: Angina Pectoris; Aspirin; Blood Platelets; Cardiovascular Diseases; Cerebrovascular Disorders; Clofi | 1979 |
Antiplatelet drugs-a new pharmacologic approach to the prevention of thrombosis.
Topics: Anticoagulants; Aspirin; Blood Platelets; Brain; Clofibrate; Dextrans; Dipyridamole; Humans; Ischemi | 1976 |
Antithrombotic drugs: part II.
Topics: Anabolic Agents; Ancrod; Animals; Aspirin; Blood Platelets; Clofibrate; Dextrans; Dipyridamole; Fibr | 1976 |
Platelets and thromboembolism.
Topics: Arteriovenous Shunt, Surgical; Aspirin; Blood Platelets; Cerebrovascular Disorders; Clofibrate; Dext | 1976 |
Platelet-inhibiting drugs in the prevention of clinical thrombotic disease (second of three parts).
Topics: Aged; Arterial Occlusive Diseases; Arteriosclerosis; Aspirin; Cardiac Catheterization; Clinical Tria | 1975 |
Advances in medicine.
Topics: Anemia, Macrocytic; Anti-Arrhythmia Agents; Anticoagulants; Azathioprine; Chemical and Drug Induced | 1972 |
30 trials available for clofibrate and Myocardial Infarction
| Article | Year |
|---|---|
W.H.O. cooperative trial on primary prevention of ischaemic heart disease using clofibrate to lower serum cholesterol: mortality follow-up. Report of the Committee of Principal Investigators.
Topics: Cholesterol; Clinical Trials as Topic; Clofibrate; Coronary Disease; Double-Blind Method; Follow-Up | 1980 |
Changes in the fatty acid composition of the plasma lipid esters during lipid-lowering treatment with diet, clofibrate and niceritrol. Reduction of the proportion of linoleate by clofibrate but not by niceritrol.
Topics: Aged; Cholesterol Esters; Clinical Trials as Topic; Clofibrate; Diet Therapy; Dose-Response Relation | 1980 |
Selection and results of antiplatelet therapy in the prevention of stroke and myocardial infarction.
Topics: Adult; Aspirin; Blood Platelets; Cerebrovascular Disorders; Clinical Trials as Topic; Clofibrate; Di | 1981 |
The randomized clinical trial: bias in analysis.
Topics: Acute Disease; Alprenolol; Atenolol; Clinical Trials as Topic; Clofibrate; Double-Blind Method; Huma | 1981 |
The cardiovascular disease programme of WHO/EURO. A critical review of its first 12 years.
Topics: Adult; Cardiovascular Diseases; Clinical Trials as Topic; Clofibrate; Coronary Disease; Double-Blind | 1981 |
Role of blood platelets in coronary artery disease.
Topics: Adrenergic beta-Antagonists; Arrhythmias, Cardiac; Aspirin; Clinical Trials as Topic; Clofibrate; Co | 1979 |
The coronary drug project--findings with regard to estrogen, dextrothyroxine, clofibrate and niacin.
Topics: Adult; Cholesterol; Clinical Trials as Topic; Clofibrate; Coronary Disease; Dextrothyroxine; Double- | 1977 |
Cholesterol, coronaries, clofibrate and death.
Topics: Adult; Cholesterol; Clinical Trials as Topic; Clofibrate; Coronary Disease; Death, Sudden; Humans; H | 1978 |
[Clinical application and evaluation of anti-platelet agents].
Topics: Aged; Aspirin; Blood Platelets; Clinical Trials as Topic; Clofibrate; Dipyridamole; Drug Evaluation; | 1978 |
Cooperative clofibrate trial.
Topics: Cholesterol; Clinical Trials as Topic; Clofibrate; Coronary Disease; Follow-Up Studies; Humans; Male | 1979 |
Reduction of myocardial reinfarction by the combined treatment with clofibrate and nicotinic acid.
Topics: Cholesterol; Clofibrate; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Myocardial In | 1977 |
[Results of the Coronary Drug Project--routine treatment of infarct patients with serum lipid reductants].
Topics: Clinical Trials as Topic; Clofibrate; Estrogens; Humans; Lipids; Myocardial Infarction; Nicotinic Ac | 1975 |
The current status of platelet suppressive drugs in the treatment of thrombosis.
Topics: Aged; Arteriovenous Shunt, Surgical; Aspirin; Blood Platelets; Cardiac Catheterization; Cell Surviva | 1975 |
Platelet-inhibiting drugs in the prevention of clinical thrombotic disease (second of three parts).
Topics: Aged; Arterial Occlusive Diseases; Arteriosclerosis; Aspirin; Cardiac Catheterization; Clinical Tria | 1975 |
Reduction of mortality in the Stockholm Ischaemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid.
Topics: Aged; Cholesterol; Clinical Trials as Topic; Clofibrate; Coronary Disease; Female; Humans; Lipids; L | 1988 |
Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin.
Topics: Adult; Aspirin; Clofibrate; Dextrothyroxine; Estrogens; Follow-Up Studies; Humans; Male; Middle Aged | 1986 |
The Coronary Drug Project. Initial findings leading to modifications of its research protocol.
Topics: Adult; Anticholesteremic Agents; Clinical Trials as Topic; Clofibrate; Coronary Disease; Dextrothyro | 1970 |
The coronary drug project. Findings leading to further modifications of its protocol with respect to dextrothyroxine. The coronary drug project research group.
Topics: Adult; Cholesterol; Clofibrate; Coronary Disease; Dextrothyroxine; Electrocardiography; Estrogens, C | 1972 |
The Coronary Drug Project. Findings leading to discontinuation of the 2.5-mg day estrogen group. The coronary Drug Project Research Group.
Topics: Adult; Anticholesteremic Agents; Clinical Trials as Topic; Clofibrate; Coronary Disease; Dextrothyro | 1973 |
Clofibrate and coronary heart disease.
Topics: Adult; Aged; Clinical Trials as Topic; Clofibrate; Coronary Circulation; Coronary Disease; Evaluatio | 1972 |
The coronary drug project. Design, methods, and baseline results.
Topics: Adult; Alkaline Phosphatase; Anticholesteremic Agents; Bilirubin; Blood Glucose; Blood Pressure; Blo | 1973 |
Clofibrate in the treatment and prevention of ischaemic heart disease: recent trials.
Topics: Angina Pectoris; Cholesterol; Clinical Trials as Topic; Clofibrate; Coronary Disease; Humans; Lipopr | 1972 |
Long-term therapy of ischaemic heart disease.
Topics: Angina Pectoris; Cholesterol; Clinical Trials as Topic; Clofibrate; Coronary Disease; Death, Sudden; | 1972 |
Clofibrate for prevention of myocardial infarction.
Topics: Angina Pectoris; Clinical Trials as Topic; Clofibrate; Coronary Disease; Humans; Hypercholesterolemi | 1973 |
Clofibrate in ischaemic heart disease.
Topics: Clinical Trials as Topic; Clofibrate; Coronary Disease; Humans; Myocardial Infarction | 1971 |
Trial of clofibrate in the treatment of ischaemic heart disease. Five-year study by a group of physicians of the Newcastle upon Tyne region.
Topics: Adult; Angina Pectoris; Anticoagulants; Cholesterol; Clinical Trials as Topic; Clofibrate; Coronary | 1971 |
Ischaemic heart disease: a secondary prevention trial using clofibrate. Report by a research committee of the Scottish Society of Physicians.
Topics: Adult; Aged; Angina Pectoris; Cholesterol; Clinical Trials as Topic; Clofibrate; Coronary Disease; E | 1971 |
Secondary prevention trials using clofibrate: a joint commentary on the Newcastle and Scottish trials.
Topics: Adult; Aged; Angina Pectoris; Cholesterol; Clinical Trials as Topic; Clofibrate; Coronary Disease; D | 1971 |
Clofibrate in ischemic heart disease.
Topics: Angina Pectoris; Clofibrate; Humans; Myocardial Infarction; Placebos | 1972 |
Clofibrate in coronary heart disease. Effect on morbidity and mortality.
Topics: Adult; Age Factors; Angina Pectoris; Blood Pressure; Cholesterol; Clofibrate; Coronary Disease; Huma | 1972 |
66 other studies available for clofibrate and Myocardial Infarction
| Article | Year |
|---|---|
Clofibrate Treatment Decreases Inflammation and Reverses Myocardial Infarction-Induced Remodelation in a Rodent Experimental Model.
Topics: Animals; Clofibrate; Cytokines; Disease Models, Animal; Hypolipidemic Agents; Inflammation; Inflamma | 2019 |
Peroxisome proliferator-activated receptors (PPAR) downregulate the expression of pro-inflammatory molecules in an experimental model of myocardial infarction.
Topics: Animals; Clofibrate; Disease Models, Animal; Down-Regulation; Gene Expression Regulation; Inflammati | 2016 |
Ligands of the peroxisome proliferator-activated receptor-PPAR-a reduce myocardial infarct size.
Topics: Animals; Cardiotonic Agents; Clofibrate; Disease Models, Animal; Heart; Hemodynamics; Ligands; Male; | 2002 |
EFFECT OF ETHYL CHLOROPHENOXYISOBUTYRATE WITH OR WITHOUT ANDROSTERONE ON PLATELET STICKINESS.
Topics: Androsterone; Biomedical Research; Blood Platelets; Butyrates; Cholesterol; Clofibrate; Drug Therapy | 1964 |
The myocardial infarct size-limiting and antiarrhythmic effects of acyl-CoA:cholesterol acyltransferase inhibitor VULM 1457 protect the hearts of diabetic-hypercholesterolaemic rats against ischaemia/reperfusion injury both in vitro and in vivo.
Topics: Animals; Anti-Arrhythmia Agents; Cholesterol, Dietary; Clofibrate; Diabetes Mellitus, Experimental; | 2007 |
Why measure cholesterol after myocardial infarction, and when?
Topics: Adult; Cholesterol; Clofibrate; Dietary Fats; Humans; Male; Middle Aged; Myocardial Infarction; Nico | 1984 |
Reduced incidence of cardiovascular complications and mortality in hyperlipoproteinemia (HLP) with effective lipid correction. The Dresden HLP study.
Topics: Adolescent; Adult; Cerebrovascular Disorders; Cholesterol; Cholestyramine Resin; Clofibrate; Combine | 1984 |
[Clofibrate therapy--the status quo].
Topics: Carcinogens; Cholelithiasis; Cholesterol; Clofibrate; Humans; Hyperlipoproteinemias; Lipoproteins, L | 1982 |
[Study of clofibrate. The opinion of Prof. D. Kritchevsky].
Topics: Adult; Arteriosclerosis; Cholelithiasis; Clofibrate; Coronary Disease; Drug Evaluation; Humans; Hype | 1980 |
What happens after lipoprotein lipase? A low fatty acid incorporation into adipose tissue (FIAT) in hypertriglyceridaemia-experimental and clinical studies.
Topics: Adipose Tissue; Adult; Aged; Clofibrate; Fatty Acids; Glucose; Humans; Lipolysis; Lipoprotein Lipase | 1981 |
Effect of combined clofibrate--nicotinic acid treatment in ischemic heart disease.
Topics: Clofibrate; Coronary Disease; Coronary Vessels; Drug Therapy, Combination; Female; Humans; Lipids; M | 1980 |
[Anti-platelet-aggregating drugs. Clinical pharmacology and therapeutic use].
Topics: Aspirin; Blood Platelet Disorders; Brain Ischemia; Clofibrate; Coronary Disease; Dipyridamole; Human | 1980 |
Cholesterol-lowering drugs. Some drugs with demonstrated efficacy but different benefits in primary and secondary prevention.
Topics: Anticholesteremic Agents; Bezafibrate; Cholestyramine Resin; Clinical Trials as Topic; Clofibrate; F | 1999 |
Lipid-lowering drug use and cardiovascular events after myocardial infarction.
Topics: Cholesterol; Clofibrate; Cohort Studies; Coronary Artery Disease; Coronary Disease; Female; Humans; | 2002 |
Ligands of the peroxisome proliferator-activated receptors (PPAR-gamma and PPAR-alpha) reduce myocardial infarct size.
Topics: Adult; Animals; Cardiotonic Agents; Cell Adhesion Molecules; Cell Line; Cells, Cultured; Chemokine C | 2002 |
Editorial: Lipid-lowering drugs after myocardial infarction.
Topics: Cholesterol; Clofibrate; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipids; Myocardial Infarctio | 1975 |
Effect of clofibrate on plasma proteins including components of the hemostatic mechanism.
Topics: Adult; Arteriosclerosis; Blood Proteins; Clofibrate; Diabetes Mellitus; Fibrinolysin; Hemostasis; Hu | 1976 |
[Serum lipid-lowering drugs following myocardial infarction].
Topics: Cholesterol; Clofibrate; Dextrothyroxine; Estrogens, Conjugated (USP); Female; Germany, West; Humans | 1975 |
The Coronary Drug Project: implications for clinical care.
Topics: Clofibrate; Dextrothyroxine; Estrogens; Estrogens, Conjugated (USP); Humans; Hypolipidemic Agents; M | 1977 |
[Correction of lipid exchange with heparin and miscleron in patients with ischemic heart disease].
Topics: Adult; Clofibrate; Female; Heparin; Humans; Hyperlipidemias; Male; Middle Aged; Myocardial Infarctio | 1979 |
[The study of clofibrate. The viewpoint of Professor D. Kritchevsky interviewed by V. Fabbrocini].
Topics: Arteriosclerosis; Clofibrate; Coronary Disease; Humans; Hypercholesterolemia; Hyperlipidemias; Myoca | 1979 |
[Antiplatelet drugs (author's transl)].
Topics: Aspirin; Blood Platelets; Clofibrate; Dipyridamole; Female; Humans; Hydroxychloroquine; Ischemic Att | 1979 |
Platelet suppressing drugs in arterial disease.
Topics: Anticoagulants; Aspirin; Blood Platelets; Cerebrovascular Disorders; Clofibrate; Humans; Myocardial | 1978 |
Antiplatelet agents in coronary disease: are they of prophylactic value?
Topics: Angina Pectoris; Aspirin; Cardiopulmonary Bypass; Clofibrate; Coronary Disease; Dipyridamole; Fibrin | 1978 |
Protective effects of clofibrate on isoproterenol-induced myocardial infarction in arteriosclerotic and non-arteriosclerotic rats.
Topics: Alanine Transaminase; Animals; Aspartate Aminotransferases; Blood Glucose; Blood Urea Nitrogen; Clof | 1978 |
Coronary Drug Project report on clofibrate and niacin.
Topics: Clofibrate; Humans; Hypercholesterolemia; Male; Middle Aged; Myocardial Infarction; Nicotinic Acids | 1978 |
Coronary drug project.
Topics: Clofibrate; Electrocardiography; Humans; Male; Myocardial Infarction; Nicotinic Acids | 1978 |
[Serum lipid reduction with clofibrate reduces the incidence of myocardial infarct].
Topics: Clofibrate; Humans; Lipids; Myocardial Infarction | 1978 |
[Myocardial infarct and clofibrate--again].
Topics: Adult; Cholesterol; Clofibrate; Humans; Male; Middle Aged; Myocardial Infarction | 1978 |
Clofibrate and the primary prevention of ischaemic heart disease.
Topics: Adult; Cholesterol; Clofibrate; Coronary Disease; Humans; Male; Middle Aged; Myocardial Infarction | 1978 |
[Indications, contraindications and adverse effects of drugs in cardiovascular diseases. Treatment of hyperlipoproteinemia].
Topics: Cholestyramine Resin; Clofibrate; Humans; Hyperlipidemias; Myocardial Infarction; Nicotinic Acids | 1977 |
Effect of drugs of platelets and complications of vascular disease.
Topics: Animals; Anticoagulants; Aspirin; Blood Coagulation; Blood Platelets; Clofibrate; Coronary Disease; | 1977 |
[Drug therapy for myocardial infarct during rehabilitation period].
Topics: Adult; Aged; Clofibrate; Female; Humans; Isosorbide Dinitrate; Male; Middle Aged; Myocardial Infarct | 1977 |
Dextrothyroxine for lowering cholesterol.
Topics: Angina Pectoris; Cholestyramine Resin; Clofibrate; Dextrothyroxine; Humans; Hypercholesterolemia; Hy | 1976 |
Are agents affecting platelet function clinically useful in patients with coronary artery disease?
Topics: Angina Pectoris; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Platelets; Clofibrate; Coro | 1976 |
Editorial: After a coronary.
Topics: Angina Pectoris; Cholesterol; Clofibrate; Coronary Disease; Humans; Myocardial Infarction; Nicotinic | 1975 |
Lipid-lowering drugs.
Topics: Cellulose; Cholestyramine Resin; Clofibrate; Drug Evaluation; Humans; Hyperlipidemias; Lipids; Myoca | 1975 |
[Lipid reduction and myocardial infarct].
Topics: Adult; Clofibrate; Humans; Lipids; Male; Middle Aged; Myocardial Infarction; Nicotinic Acids | 1975 |
[Value of lipid lowering drugs after myocardial infarction: results of the coronary drug project 1975 (author's transl)].
Topics: Cholesterol; Clofibrate; Humans; Myocardial Infarction; Nicotinic Acids; Prognosis; Smoking; Triglyc | 1975 |
Clinical trials on the efficacy of pharmacologic intervention reducing mortality from cardiovascular diseases.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Aspirin; Cardiovascular Diseases; Clofibrate; | 1985 |
Improved myocardial performance induced by clofibrate during reperfusion after acute myocardial infarction.
Topics: Animals; Catalase; Clofibrate; Coronary Circulation; Creatine Kinase; Fatty Acids; Fatty Acids, None | 1988 |
[Risks and benefits of a treatment: as exemplified by clofibrate].
Topics: Clofibrate; Humans; Hypercholesterolemia; Lipid Metabolism; Myocardial Infarction; Risk | 1987 |
[Therapy and prevention of arteriosclerosis].
Topics: Adult; Aged; Animals; Anticoagulants; Aorta; Arteriosclerosis; Blood Coagulation Disorders; Blood Co | 1971 |
When a drug is the culprit.
Topics: Adult; Aged; Angina Pectoris; Arrhythmias, Cardiac; Clofibrate; Depression; Drug-Related Side Effect | 1973 |
Metabolic relationships among the plasma lipoproteins. Reciprocal changes in the concentrations of very low and low density lipoproteins in man.
Topics: Adolescent; Adult; Angina Pectoris; Body Weight; Cholesterol; Clofibrate; Coronary Disease; Female; | 1972 |
[Role of magnesium, potassium, antikaliuretic agents and hypocholesteremic agents in cardiac lesion development in rats fed a thrombogenic diet and Na 2 HPO 4 ].
Topics: Animals; Anticholesteremic Agents; Clofibrate; Diet, Atherogenic; Diuretics; Estrogens, Conjugated ( | 1972 |
[Long-term medicinal prevention in patients who have suffered myocardial infarction].
Topics: Anti-Arrhythmia Agents; Anticoagulants; Antihypertensive Agents; Clofibrate; Dipyridamole; Drug Ther | 1974 |
Platelet stickiness and serum cholesterol levels after myocardial infarction treated with clofibrate and heparine.
Topics: Arteriosclerosis; Cholesterol; Clofibrate; Female; Heparin; Humans; Male; Middle Aged; Myocardial In | 1972 |
Ischemic heart disease: a secondary prevention trial using clofibrate (Atromid-S).
Topics: Adult; Aged; Angina Pectoris; Cholesterol; Clofibrate; Coronary Disease; Death, Sudden; Electroencep | 1972 |
Warfarin dosage, clofibrate, and age of patient.
Topics: Adult; Age Factors; Clofibrate; Drug Synergism; Humans; Middle Aged; Myocardial Infarction; Warfarin | 1973 |
[The importance of determining the type of hyperlipidemia for lipotropic therapy of atherosclerosis].
Topics: Adult; Arteriosclerosis; Cholesterol; Cholestyramine Resin; Clofibrate; Coronary Disease; Electropho | 1973 |
Editorial: The value of clofibrate in coronary heart disease.
Topics: Angina Pectoris; Clofibrate; Coronary Disease; Death, Sudden; Evaluation Studies as Topic; Humans; L | 1974 |
The effect of clofibrate on serum and faecal lipids.
Topics: Adult; Angina Pectoris; Bile Acids and Salts; Cholesterol; Clofibrate; Feces; Female; Humans; Hyperc | 1972 |
Type IV hyperlipoproteinemia in a consanguinous family.
Topics: Adult; Aged; Allopurinol; Clofibrate; Consanguinity; Dietary Carbohydrates; Female; Glucose Toleranc | 1972 |
Trial of clofibrate.
Topics: Angina Pectoris; Clofibrate; Electrocardiography; Evaluation Studies as Topic; Female; Humans; Male; | 1972 |
Clofibrate.
Topics: Clofibrate; Humans; Myocardial Infarction | 1972 |
Effect of long-term administration of clofibrate on the composition of blood lipids in patients with atherosclerosis.
Topics: Adult; Aged; Arteriosclerosis; Cholesterol; Clofibrate; Fatty Acids, Nonesterified; Female; Humans; | 1972 |
[Results of a 5-year study of the action of clofibrate in the treatment of ischemic cardiopathy].
Topics: Adult; Cholesterol; Clofibrate; Coronary Disease; Female; Humans; Male; Middle Aged; Myocardial Infa | 1971 |
[Evaluation of clofibrate therapy in peripheral arteriopathy].
Topics: Adult; Aged; Arteriosclerosis; Cholesterol; Clofibrate; Humans; Intermittent Claudication; Middle Ag | 1971 |
[Physiological and pharmacological aspects of fibrinolysis].
Topics: Adrenal Cortex Hormones; Anabolic Agents; Arteriosclerosis Obliterans; Biguanides; Blood Coagulation | 1971 |
[Antilipidemic agents].
Topics: Adult; Alcohols; Anticholesteremic Agents; Biguanides; Blood Protein Disorders; Body Weight; Cholest | 1971 |
[Comparison of the effect of heparin and atromide-S on the adhesiveness of platelets in the postinfarction period].
Topics: Clofibrate; Heparin; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Adhesiveness | 1971 |
A long-time study of the blood lipids of two students of atherosclerosis.
Topics: Age Factors; Aged; Arteriosclerosis; Body Weight; Cholesterol; Clofibrate; Coronary Disease; Diet; D | 1969 |
Prevention of ischaemic heart disease. Possibilities and problems.
Topics: Adult; Age Factors; Aged; Cholesterol; Clofibrate; Coronary Disease; Czechoslovakia; Diet; Female; H | 1970 |
[Unorthodox reflections about arteriosclerosis].
Topics: Animals; Arteriosclerosis; Cholesterol; Clofibrate; Heart Failure; Humans; Hypercholesterolemia; Hyp | 1970 |
Xanthomatosis, hyperlipoproteinaemia (type II, Fredrickson), gout, cardiac infarction.
Topics: Adult; Cholesterol; Clofibrate; Gout; Humans; Hyperlipidemias; Indomethacin; Lipoproteins; Male; Myo | 1971 |